INNO-206: Additional Phase Ib/II data

Data from 16 evaluable patients with soft tissue sarcoma (STS) in an open-label, dose-escalation Phase Ib/II trial showed that IV INNO-206 given on day 1 of each 21-day cycle for up to 8 consecutive c...